Dr. Matthias Holdhoff

Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as an Elite provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Pediatric Low-Grade Glioma (pLGG).

Mayer Gorbaty is an Oncologist and a Hematologist in Clinton, Maryland. Dr. Gorbaty is rated as a Distinguished provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Multiple Myeloma. Dr. Gorbaty is currently accepting new patients.

Dr. Solmaz Sahebjam is a medical oncologist and an associate professor of oncology at Johns Hopkins University School of Medicine. Her expertise is in primary and metastatic brain tumors, breast cancer, and the development of new drugs for cancer. She earned her medical degree from Iran University of Medical Sciences, followed by a post-doctoral research fellowship at Shriners Hospital, McGill University in Montreal. Dr. Sahebjam completed residency training in internal medicine at Saint Vincent Hospital, followed by a fellowship in internal medicine at the University of Ottawa in Canada. She continued her training with a residency in medical oncology at McGill University in Canada followed by a fellowship in early-phase drug development, breast oncology, and neurooncology at Princess Margaret Hospital, University of Toronto in Canada. Dr. Sahebjam’s research is focused on the development of novel therapeutic regimens for the treatment of cancer including breast and central nervous system malignancies. Over the years, she has led and contributed to numerous clinical trials some of which have resulted in new treatment options for patients with cancer. Dr. Sahebjam is rated as an Elite provider by MediFind in the treatment of Medulloblastoma. Her top areas of expertise are Glioma, Brain Tumor, Glioblastoma, Astrocytoma, and Awake Craniotomy.